Thank you for donating!

You can donate using the following services.

Need support today?

Main menu

Contact Us

Our address

NPUK

Suite 2, Vermont House, Concord, Washington, Tyne and Wear, NE37 2SQ

Have a question? We are here to help.

Fill out the form below, or get in touch using the contact details listed on the left.

Your name

Email address

Telephone number

Your enquiry

Latest news

20.02.20

Cyclo Therapeutics Announces Completion of Enrollment in its Phase I/II Trial to Evaluate Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer’s Disease, today announced that it has completed patient enrollment in its Phase I/II trial to evaluate the safety, tolerability, and efficacy of Trappsol® Cyclo™ administered intravenously to Niemann-Pick Disease Type C1 (NPC1) patients...

Read more

12.02.20

Last Patient Last Visit in Cyclo Therapeutics’ Phase I Trial in Niemann-Pick Type C

GAINESVILLE, FL – (Businesswire) – February 11, 2020 – Cyclo Therapeutics, Inc. (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that the last patient has undergone the final assessment in its Phase I trial to evaluate the safety and tolerability of Trappsol® Cyclo™ administered intravenously to NPC patients.

Read more
View all news Subscribe

2020 Niemann-Pick UK (NPUK). Registered Charity: England and Wales (1144406) / Scotland (SCO45407). Registered as a company limited by guarantee in England and Wales (07775835).

Donate today